NCT01187199 2026-04-16
Phase I Trial of Bevacizumab and Temsirolimus in Combination With 1) Carboplatin, 2) Paclitaxel, 3) Sorafenib for the Treatment of Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
Clinical Trials
69 trialsNCT01375829 2026-04-13
Ixabepilone and Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Active not recruiting
NCT02215720 2026-03-20
TORERO
Gustave Roussy, Cancer Campus, Grand Paris
Phase 1 Completed
NCT02389309 2026-03-09
Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03203525 2026-02-25
Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01087554 2026-01-16
Sirolimus or Everolimus or Temsirolimus and Vorinostat in Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT01552434 2025-10-14
Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT02420613 2025-04-02
Vorinostat and Temsirolimus With or Without Radiation Therapy in Treating Younger Patients With Newly Diagnosed or Progressive Diffuse Intrinsic Pontine Glioma
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01529593 2025-03-24
Temsirolimus in Combination With Metformin in Patients With Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Terminated
NCT02343718 2023-08-04
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
Canadian Cancer Trials Group
Phase 1 Completed
NCT01614197 2023-07-27
A Trial of Temsirolimus With Etoposide and Cyclophosphamide in Children With Relapsed Acute Lymphoblastic Leukemia and Non-Hodgkins Lymphoma
Therapeutic Advances in Childhood Leukemia Consortium
Phase 1 Completed
NCT02238496 2023-05-25
Perifosine and Torisel (Temsirolimus) for Recurrent/Progressive Malignant Gliomas
Columbia University
Phase 1 Completed
NCT00593060 2023-05-24
Temsirolimus (CCI-770, Torisel) Combined With Cetuximab in Cetuximab-Refractory Colorectal Cancer
Massachusetts General Hospital
Phase 1 Completed
NCT01174199 2022-10-03
Temsirolimus and Vorinostat in Treating Patients With Metastatic Prostate Cancer
Roswell Park Cancer Institute
Phase 1 Terminated
NCT01065662 2021-04-21
AZD2171 and Temsirolimus in Patients With Advanced Gynecological Malignancies
Dana-Farber Cancer Institute
Phase 1 Completed
NCT01596140 2020-06-04
Vemurafenib in Combination With Everolimus or Temsirolimus With Advanced Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01008917 2019-05-09
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma
University of California, San Francisco
Phase 1 Completed
NCT00909831 2019-04-16
Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment
Abramson Cancer Center at Penn Medicine
Phase 1 Completed
NCT00761644 2019-04-11
Doxil, Bevacizumab and Temsirolimus Trial
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00838539 2018-09-18
Study Evaluating Neratinib In Combination With Temsirolimus In Subjects With Solid Tumors
Puma Biotechnology, Inc.
Phase 1 Completed
NCT01378377 2018-07-30
Combination Trial of Pimasertib (MSC1936369B) With Temsirolimus
EMD Serono
Phase 1 Terminated
NCT00784914 2018-04-17
A Feasibility, Dose-Escalation Study Using Intracerebral Microdialysis to Assess the Neuropharmacodynamics of Temsirolimus in Patients With Primary or Metastatic Brain Tumors
City of Hope Medical Center
Phase 1 Completed
NCT00787969 2018-01-09
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
Phase 1 Completed
NCT00998036 2017-12-13
Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors
Columbia University
Phase 1 Completed
NCT00610493 2017-12-08
Bevacizumab and Temsirolimus in Patients With Advanced Malignancy
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01182883 2017-07-02
A Phase I Study of IMC-A12 in Combination With Temsirolimus in Pediatric Patients With Recurrent or Refractory Solid Tumors
National Institutes of Health Clinical Center (CC)
Phase 1 Withdrawn
NCT01049841 2017-03-10
Perifosine With Temsirolimus for Recurrent Pediatric Solid Tumors
Memorial Sloan Kettering Cancer Center
Phase 1 Completed
NCT00703625 2017-03-07
Phase I Study of Docetaxel and Temsirolimus in Resistant Solid Malignancies
Washington University School of Medicine
Phase 1 Completed
NCT01204450 2016-12-23
Temsirolimus and Valproic Acid in Treating Young Patients With Relapsed Neuroblastoma, Bone Sarcoma, or Soft Tissue Sarcoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Terminated
NCT01155258 2016-06-13
Temsirolimus and Vinorelbine Ditartrate in Treating Patients With Unresectable or Metastatic Solid Tumors
University of Southern California
Phase 1 Completed
NCT01183663 2016-06-03
Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT00693433 2015-12-04
Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01122615 2015-11-18
Sunitinib Plus Temsirolimus in Patients With Renal Cell Cancer (RCC)
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01902160 2015-11-09
Temsirolimus and Brentuximab Vedotin in Treating Patients With Relapsed or Refractory Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00678769 2015-11-04
Cixutumumab and Temsirolimus in Treating Patients With Locally Advanced or Metastatic Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01625156 2015-10-20
Tivantinib and Temsirolimus in Treating Patients With Solid Tumors That is Metastatic or Cannot be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT01548482 2015-10-06
Trebananib And Temsirolimus in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 1 Completed
NCT00996346 2015-09-01
Phase I/II Study of Irinotecan and Temsirolimus in Patients With Refractory Sarcomas
New Mexico Cancer Research Alliance
Phase 1 Terminated
NCT01403415 2015-07-10
Temsirolimus, Dexamethasone, Mitoxantrone Hydrochloride, Vincristine Sulfate, and Pegaspargase in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Non-Hodgkin Lymphoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT00770263 2015-06-03
Erlotinib and Temsirolimus for Solid Tumors
Washington University School of Medicine
Phase 1 Completed
NCT00255658 2015-04-15
Sorafenib and Temsirolimus in Treating Patients With Unresectable or Metastatic Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01529138 2015-04-13
Study of Axitinib and Temsirolimus in Solid Tumors
Emory University
Phase 1 Completed
NCT00788580 2015-03-06
S0718 Pazopanib and Temsirolimus in Treating Patients With Advanced Solid Tumors
SWOG Cancer Research Network
Phase 1 Withdrawn
NCT00408655 2014-06-19
Temsirolimus, Carboplatin, and Paclitaxel in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01198184 2014-05-30
Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 and Temsirolimus in Treating Patients With Advanced Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT00880282 2014-04-29
Cixutumumab and Temsirolimus in Treating Younger Patients With Solid Tumors That Have Recurred or Not Responded to Treatment
National Cancer Institute (NCI)
Phase 1 Completed
NCT00349206 2014-04-10
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma
National Cancer Institute (NCI)
Phase 1 Completed
NCT01141244 2014-04-10
Temsirolimus, Irinotecan Hydrochloride, and Temozolomide in Treating Younger Patients With Relapsed or Refractory Solid Tumors
National Cancer Institute (NCI)
Phase 1 Completed
NCT01050985 2014-02-13
A Study of Temsirolimus Plus Capecitabine in Patients With Advanced Cancer
Georgetown University
Phase 1 Completed